New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2012
10:26 EDTPDH, EFC, TWO, HCLP, CYTR, SEE, FNSR, BMS, ATR, APKTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acme Packet (APKT) initiated with a Sector Perform at RBC Capital... AptarGroup (ATR) initiated with a Neutral at JPMorgan... Bemis (BMS) initiated with a Neutral at JPMorgan... CytRx (CYTR) initiated with an Outperform at Rodman & Renshaw... Ellington Financial (EFC) initiated with a Buy at BofA/Merrill... Finisar (FNSR) initiated with a Sector Perform at RBC Capital... Hi-Crush Partners (HCLP) initiated with a Buy at UBS... Hi-Crush Partners initiated with an Outperform at Credit Suisse... PetroLogistics (PDH) initiated with a Buy at Dahlman Rose... Sealed Air (SEE) initiated with an Overweight at JPMorgan... Two Harbors (TWO) initiated with a Buy at BofA/Merrill.
News For APKT;ATR;BMS;CYTR;EFC;FNSR;HCLP;PDH;SEE;TWO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
09:04 EDTCYTRCytRx's aldoxorubicin shows positive Phase 2 results for brain cancer
CytRx announced positive updated results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme, a deadly form of brain cancer. The open-label, multisite trial is designed to investigate the preliminary efficacy and safety of aldoxorubicin in patients whose tumors have progressed following prior treatment with surgery, radiation and temozolomide. 18 study subjects have received between 1 and 14 cycles of aldoxorubicin, with 4 subjects continuing to receive aldoxorubicin treatment. 2 subjects diagnosed with tumor progression following aldoxorubicin treatment demonstrated no microscopic evidence of tumor tissue after resection. Fourteen of 18 subjects discontinued aldoxorubicin treatment, although there is a significant possibility that some of the patients experienced pseudo-progression. Following discontinuation of aldoxorubicin treatment, 10 of 14 subjects received treatment with bevacizumab for 1 to 14 cycles. Deaths have occurred in only 4 of 18 subjects to date, with survival duration so far of up to 10 plus months. Aldoxorubicin was well tolerated at both dose levels with all adverse events consistent with known doxorubicin toxicities, but not cardiotoxity.
May 19, 2015
07:35 EDTSEESealed Air announces price increases for European Product Care, Food Care
Subscribe for More Information
May 15, 2015
16:34 EDTTWOTwo Harbors files automatic mixed securities shelf
Subscribe for More Information
May 14, 2015
10:00 EDTHCLPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:42 EDTHCLPHi-Crush Partners downgraded to Neutral at BofA/Merrill
BofA/Merrill downgraded Hi-Crush Partners to Neutral from Buy. The firm is forecasting frac sand demand to decline 25%-30% in 2015, resulting in reduced sales volume outlook for the company. BofA/Merrill lowered its price target to $35 from $45.
06:28 EDTHCLPHi-Crush Partners downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
May 12, 2015
09:36 EDTCYTRCytRx management to meet with Oppenheimer
Subscribe for More Information
May 11, 2015
09:59 EDTHCLPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:29 EDTHCLPHi-Crush Partners downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use